Insider · CIK 0001405253

Farrow Jeffrey S

Reports to the SEC for 6 companies · BOTHELL, WA

sec.gov

Transactions

Companies

Filings

CIK

0001405253

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-27	ACHVACHIEVE LIFE SCIENCES, INC. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2026-07-27	ACHVACHIEVE LIFE SCIENCES, INC. · Restricted Stock Unit (RSU)A Award	Director	AAward	+16.7K sh	—	—	16,700
2026-06-16	TARSTarsus Pharmaceuticals, Inc.S Sale	See Remarks	SSale	−14.4K sh	$60.95	−$877K	56,801
2026-06-15	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+27.9K sh	—	—	71,197
2026-06-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−27.9K sh	—	—	27,882
2026-05-29	ACHVACHIEVE LIFE SCIENCES, INC. · Stock Option (right to buy)A Award	Director	AAward	+47.3K sh	—	—	47,250
2026-03-19	TARSTarsus Pharmaceuticals, Inc.S Sale	See Remarks	SSale	−2,186 sh	$67.00	−$146K	43,316
2026-03-18	TARSTarsus Pharmaceuticals, Inc.S Sale	See Remarks	SSale	−2,133 sh	$68.71	−$147K	45,502
2026-03-17	TARSTarsus Pharmaceuticals, Inc.S Sale	See Remarks	SSale	−2,111 sh	$69.42	−$147K	47,635
2026-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−8,020 sh	—	—	16,040
2026-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−5,022 sh	—	—	15,067
2026-03-15	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+13K sh	—	—	49,746
2026-03-05	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+30.7K sh	—	—	30,724
2026-03-05	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	See Remarks	AAward	+19.3K sh	—	—	19,306
2025-06-17	TARSTarsus Pharmaceuticals, Inc.S Sale	See Remarks	SSale	−13.6K sh	$40.42	−$550K	36,704
2025-06-16	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+27.9K sh	—	—	50,312
2025-06-16	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−27.9K sh	—	—	55,763
2025-03-20	TARSTarsus Pharmaceuticals, Inc.S Sale	See Remarks	SSale	−1,186 sh	$50.11	−$59.4K	22,431
2025-03-19	TARSTarsus Pharmaceuticals, Inc.S Sale	See Remarks	SSale	−1,254 sh	$47.40	−$59.4K	23,617
2025-03-18	TARSTarsus Pharmaceuticals, Inc.S Sale	See Remarks	SSale	−1,284 sh	$46.29	−$59.4K	24,871
2025-03-17	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−8,019 sh	—	—	24,060
2025-03-15	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+8,019 sh	—	—	26,155
2025-03-05	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	See Remarks	AAward	+20.1K sh	—	—	20,089
2025-03-05	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+30.6K sh	—	—	30,628
2024-06-18	TARSTarsus Pharmaceuticals, Inc.S Sale	See Remarks	SSale	−10.4K sh	$27.47	−$287K	18,136
2024-06-17	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−27.9K sh	—	—	83,644
2024-06-17	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+27.9K sh	—	—	28,581
2024-03-07	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	See Remarks	AAward	+32.1K sh	—	—	32,079
2024-03-07	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+47.5K sh	—	—	47,500
2023-04-24	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+163K sh	—	—	163,397
2023-04-24	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	See Remarks	AAward	+112K sh	—	—	111,525
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−10.3K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−35K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−40K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−42.4K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−26.7K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−120K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−38.5K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−3,125 sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−26.5K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−13.8K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−38.7K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−28.6K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−9,060 sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−15.5K sh	—	—	0
2022-09-27	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−23.7K sh	—	—	10,299
2022-09-27	Global Blood Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+23.7K sh	$16.40	+$388K	26,739
2022-09-01	Global Blood Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,763 sh	—	—	34,204
2022-09-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,208 sh	—	—	15,460
2022-09-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,763 sh	—	—	13,814

Recent filings

Accepted (ET)
Jul 294
Farrow Jeffrey S0001193125-26-324238
SEC(opens sec.gov)
Jun 174
Farrow Jeffrey S0001405253-26-000013
SEC(opens sec.gov)
Jun 24
Farrow Jeffrey S0001405253-26-000011
SEC(opens sec.gov)
Mar 194
Farrow Jeffrey S0001405253-26-000007
SEC(opens sec.gov)
Mar 174
Farrow Jeffrey S0001405253-26-000005
SEC(opens sec.gov)
Mar 94
Farrow Jeffrey S0001405253-26-000003
SEC(opens sec.gov)
Jun 184
Farrow Jeffrey S0001819790-25-000102
SEC(opens sec.gov)
Mar 204
Farrow Jeffrey S0001819790-25-000054
SEC(opens sec.gov)

Companies

Address

22722 29TH DR. SE SUITE 100

BOTHELL, WA, 98021